Related Experiment Video
Updated: May 23, 2026
10:41
Wild-type Blocking PCR Combined with Direct Sequencing as a Highly Sensitive Method for Detection of Low-Frequency Somatic Mutations
Published on: March 29, 2017
Risk stratification in Waldenström macroglobulinemia.
Pierre Morel1, Giampaolo Merlini
1Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Italy. pmorel@ch-lens.fr
Expert Review of Hematology
|April 6, 2012
Summary
Waldenström macroglobulinemia (WM) requires careful risk assessment, especially when numerous treatments exist. Prognostic information is crucial for guiding therapy in this rare B-cell cancer.
Area of Science:
- Hematology
- Oncology
Background:
- Waldenström macroglobulinemia (WM) is a rare lymphoplasmacytic lymphoma characterized by IgM monoclonal gammopathy.
- A significant proportion of WM patients (≥25%) are asymptomatic at diagnosis, necessitating careful consideration for treatment initiation.
Purpose of the Study:
- To review the importance of risk assessment in managing Waldenström macroglobulinemia.
- To highlight the challenges in obtaining reliable prognostic information due to evolving treatment landscapes.
Main Methods:
- Review of existing literature on Waldenström macroglobulinemia.
- Analysis of the role of risk stratification in clinical decision-making.
- Discussion of limitations in current prognostic data.
Main Results:
- Risk assessment is vital for clinical course description and treatment guidance in WM.
- The introduction of novel therapies necessitates updated risk stratification strategies.
- Interpreting prognostic information, particularly survival estimates, requires consideration of treatment history and follow-up duration.
Conclusions:
- Effective management of Waldenström macroglobulinemia relies on robust risk assessment.
- Further research with long-term follow-up is needed to refine prognostic models for WM patients, especially those not treated with contemporary options.